Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study.

Jilek, C; Krenn, M; Sebah, D; Obermeier, R; Braune, A; Kehl, V; Schroll, S; Montalvan, S; Riegger, GA; Pfeifer, M; Arzt, M

doi:10.1093/eurjhf/hfq183

2011

Zurück
Zurück zum Anfang der Trefferliste
Dauerhafter Link zum angezeigten Objekt

Titel:: Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study.
Dokumenttyp:: Journal Article
Autor(en):: Jilek, C; Krenn, M; Sebah, D; Obermeier, R; Braune, A; Kehl, V; Schroll, S; Montalvan, S; Riegger, GA; Pfeifer, M; Arzt, M
Abstract:: Sleep disordered breathing (SDB) may contribute to disease progression in patients with chronic heart failure (CHF). The objective of this observational study was to evaluate whether SDB is a risk factor for mortality in CHF patients and whether this risk can be attenuated by treatment with positive airway pressure (PAP).We studied 296 CHF patients (median left ventricular ejection fraction 33%) who underwent in-lab polysomnography between January 2002 and December 2009. We compared (i) mortality between patients with severe SDB [apnoea-hypopnoea index (AHI) >= 22.5 h(-1)] vs. those without severe SDB (AHI < 22.5 h(-1)) and (ii) evaluated the impact of PAP treatment on mortality in those with severe SDB. After accounting for significant confounding factors (age, NYHA class, cause of CHF, diabetes, and PAP treatment), patients with severe SDB (n= 176) had a 2.0-fold increased hazard ratio for death compared with those without severe SDB [95% confidence interval (CI) 1.1-3.5, P= 0.023]. In an adjusted on-treatment analysis of the group with severe SDB, mortality was significantly less in patients using PAP (18%) compared with those with untreated SDB (52%; hazard ratio 0.4, 95% CI 0.2-0.6, P= 0.001). Mortality in the PAP-treated group was lower compared with the untreated group at any time-point of the follow-up period.The presence of severe SDB in CHF patients constitutes a significantly increased risk for death, independent of established risk factors. In CHF patients with SDB, use of PAP therapy was associated with a decreased mortality rate at any time point of the follow-up, suggesting that PAP can be safely used in such patients.
Zeitschriftentitel:: Eur J Heart Fail
Jahr:: 2011
Band / Volume:: 13
Heft / Issue:: 1
Seitenangaben Beitrag:: 68-75
Sprache:: eng
Volltext / DOI:: doi:10.1093/eurjhf/hfq183
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/20961913
Print-ISSN:: 1388-9842
TUM Einrichtung:: I. Medizinische Klinik und Poliklinik (Kardiologie); Institut für Medizinische Statistik und Epidemiologie
BibTeX